(Q38926279)

English

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies.

scientific article published on 22 August 2006

In more languages

Statements

scholarly article

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Viral evolution in macaques coinfected with CCR5- and CXCR4-tropic SHIVs in the presence or absence of vaccine-elicited anti-CCR5 SHIV neutralizing antibodies (English)

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

8

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

author name string

Brian Burke

1

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Nina R Derby

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Zane Kraft

3

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Cheryl J Saunders

4

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Chuanbin Dai

5

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Nicholas Llewellyn

6

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Irina Zharkikh

7

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Tuofu Zhu

9

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Indresh K Srivastava

10

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Susan W Barnett

11

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Leonidas Stamatatos

12

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

language of work or name

0 references

publication date

22 August 2006

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

355

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

2

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

138-151

1 reference

Europe PubMed Central

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:16920175%20AND%20SRC:MED&resulttype=core&format=json

29 December 2019

Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Critical role for Env as well as Gag-Pol in control of a simian-human immunodeficiency virus 89.6P challenge by a DNA prime/recombinant modified vaccinia virus Ankara vaccine

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Different patterns of immune responses but similar control of a simian-human immunodeficiency virus 89.6P mucosal challenge by modified vaccinia virus Ankara (MVA) and DNA/MVA vaccines.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

The ability of an oligomeric human immunodeficiency virus type 1 (HIV-1) envelope antigen to elicit neutralizing antibodies against primary HIV-1 isolates is improved following partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Elicitation of neutralizing antibodies with DNA vaccines expressing soluble stabilized human immunodeficiency virus type 1 envelope glycoprotein trimers conjugated to C3d.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Priming B cell-mediated anti-HIV envelope responses by vaccination allows for the long-term control of infection in macaques exposed to a R5-tropic SHIV.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

DNA-immunization with a V2 deleted HIV-1 envelope elicits protective antibodies in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Vaccination of macaques against pathogenic simian immunodeficiency virus with Venezuelan equine encephalitis virus replicon particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Genetic relationships determined by a DNA heteroduplex mobility assay: analysis of HIV-1 env genes

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Induction of primary virus-cross-reactive human immunodeficiency virus type 1-neutralizing antibodies in small animals by using an alphavirus-derived in vivo expression system

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Multigene DNA priming-boosting vaccines protect macaques from acute CD4+-T-cell depletion after simian-human immunodeficiency virus SHIV89.6P mucosal challenge

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Immunogenicity and protective efficacy of oligomeric human immunodeficiency virus type 1 gp140.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Comparison of vaccine strategies using recombinant env-gag-pol MVA with or without an oligomeric Env protein boost in the SHIV rhesus macaque model

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Spreading of HIV-1 subtype G and envB/gagG recombinant strains among injecting drug users in Lisbon, Portugal

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Compartmentalization of human immunodeficiency virus type 1 between blood monocytes and CD4+ T cells during infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Immunogenicity in pig-tailed macaques of poliovirus replicons expressing HIV-1 and SIV antigens and protection against SHIV-89.6P disease

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Antigenicity and immunogenicity of a synthetic human immunodeficiency virus type 1 group m consensus envelope glycoprotein

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Infectious molecular clone of a recently transmitted pediatric human immunodeficiency virus clade C isolate from Africa: evidence of intraclade recombination

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Analysis of the neutralizing antibody response elicited in rabbits by repeated inoculation with trimeric HIV-1 envelope glycoproteins.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Evidence for recombination of live, attenuated immunodeficiency virus vaccine with challenge virus to a more virulent strain.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Effect of partial and complete variable loop deletions of the human immunodeficiency virus type 1 envelope glycoprotein on the breadth of gp160-specific immune responses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Importance of hypervariable regions of HIV-1 gp120 in the generation of virus neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Measuring vaccine-induced HIV neutralization: report of a workshop.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Mucosal transmission of pathogenic CXCR4-utilizing SHIVSF33A variants in rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Distinct pathogenic sequela in rhesus macaques infected with CCR5 or CXCR4 utilizing SHIVs.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

CD8+ T cell-mediated CXC chemokine receptor 4-simian/human immunodeficiency virus suppression in dually infected rhesus macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Immunization of rhesus macaques with a DNA prime/modified vaccinia virus Ankara boost regimen induces broad simian immunodeficiency virus (SIV)-specific T-cell responses and reduces initial viral replication but does not prevent disease progression f

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Protection of macaques against SIV infection by subunit vaccines of SIV envelope glycoprotein gp160.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Novel adeno-associated virus vector vaccine restricts replication of simian immunodeficiency virus in macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Immunogenicity and ability of variable loop-deleted human immunodeficiency virus type 1 envelope glycoproteins to elicit neutralizing antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Analysis of Gag-specific cytotoxic T lymphocytes in simian immunodeficiency virus-infected rhesus monkeys by cell staining with a tetrameric major histocompatibility complex class I-peptide complex

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Heterologous envelope immunogens contribute to AIDS vaccine protection in rhesus monkeys

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Evaluation of the safety, immunogenicity, and protective efficacy of whole inactivated simian immunodeficiency virus (SIV) vaccines with conformationally and functionally intact envelope glycoproteins

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

V2 loop glycosylation of the human immunodeficiency virus type 1 SF162 envelope facilitates interaction of this protein with CD4 and CCR5 receptors and protects the virus from neutralization by anti-V3 loop and anti-CD4 binding site antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Immunization with envelope subunit vaccine products elicits neutralizing antibodies against laboratory-adapted but not primary isolates of human immunodeficiency virus type 1. The National Institute of Allergy and Infectious Diseases AIDS Vaccine Ev

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

N-linked glycosylation of the V3 loop and the immunologically silent face of gp120 protects human immunodeficiency virus type 1 SF162 from neutralization by anti-gp120 and anti-gp41 antibodies

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Vaccine protection against simian immunodeficiency virus by recombinant strains of herpes simplex virus

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Mutations in the C3 region of human and simian immunodeficiency virus envelope have differential effects on viral infectivity, replication, and CD4-dependency

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Comparative efficacy of recombinant modified vaccinia virus Ankara expressing simian immunodeficiency virus (SIV) Gag-Pol and/or Env in macaques challenged with pathogenic SIV

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Potent, persistent cellular immune responses elicited by sequential immunization of rhesus macaques with Ad5 host range mutant recombinants encoding SIV Rev and SIV Nef.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Protection against mucosal simian immunodeficiency virus SIV(mac251) challenge by using replicating adenovirus-SIV multigene vaccine priming and subunit boosting

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Highly effective control of an AIDS virus challenge in macaques by using vesicular stomatitis virus and modified vaccinia virus Ankara vaccine vectors in a single-boost protocol

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Multiple V1/V2 env variants are frequently present during primary infection with human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Fine definition of a conserved CCR5-binding region on the human immunodeficiency virus type 1 glycoprotein 120

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

A conserved HIV gp120 glycoprotein structure involved in chemokine receptor binding

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Neutralizing antibody-independent containment of immunodeficiency virus challenges by DNA priming and recombinant pox virus booster immunizations

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Viral phenotype and immune response in primary human immunodeficiency virus type 1 infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

An effective AIDS vaccine based on live attenuated vesicular stomatitis virus recombinants

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

The V1, V2, and V3 regions of the human immunodeficiency virus type 1 envelope differentially affect the viral phenotype in an isolate-dependent manner

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Replication-incompetent adenoviral vaccine vector elicits effective anti-immunodeficiency-virus immunity

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Purification, Characterization, and Immunogenicity of a Soluble Trimeric Envelope Protein Containing a Partial Deletion of the V2 Loop Derived from SF162, an R5-Tropic Human Immunodeficiency Virus Type 1 Isolate

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Changes in the immunogenic properties of soluble gp140 human immunodeficiency virus envelope constructs upon partial deletion of the second hypervariable region

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Macrophage-tropic variants initiate human immunodeficiency virus type 1 infection after sexual, parenteral, and vertical transmission

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Antibody neutralization and escape by HIV-1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Control of viremia and prevention of simian-human immunodeficiency virus-induced disease in rhesus macaques immunized with recombinant vaccinia viruses plus inactivated simian immunodeficiency virus and human immunodeficiency virus type 1 particles

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Effect of a CCR5 inhibitor on viral loads in macaques dual-infected with R5 and X4 primate immunodeficiency viruses

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Improved elicitation of neutralizing antibodies against primary human immunodeficiency viruses by soluble stabilized envelope glycoprotein trimers

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Characterization of the outer domain of the gp120 glycoprotein from human immunodeficiency virus type 1

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Selective modification of variable loops alters tropism and enhances immunogenicity of human immunodeficiency virus type 1 envelope

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Improved protection of rhesus macaques against intrarectal simian immunodeficiency virus SIV(mac251) challenge by a replication-competent Ad5hr-SIVenv/rev and Ad5hr-SIVgag recombinant priming/gp120 boosting regimen

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Genotypic and phenotypic characterization of HIV-1 patients with primary infection

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Evidence for human immunodeficiency virus type 1 replication in vivo in CD14(+) monocytes and its potential role as a source of virus in patients on highly active antiretroviral therapy

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

Phenotypic heterogeneity in a panel of infectious molecular human immunodeficiency virus type 1 clones derived from a single individual

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Native but not denatured recombinant human immunodeficiency virus type 1 gp120 generates broad-spectrum neutralizing antibodies in baboons

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Protection of macaques against intrarectal infection by a combination immunization regimen with recombinant simian immunodeficiency virus SIVmne gp160 vaccines

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Role of immune responses against the envelope and the core antigens of simian immunodeficiency virus SIVmne in protection against homologous cloned and uncloned virus challenge in Macaques

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

based on heuristic

inferred from DOI database lookup

An envelope modification that renders a primary, neutralization-resistant clade B human immunodeficiency virus type 1 isolate highly susceptible to neutralization by sera from other clades.

1 reference

https://api.crossref.org/works/10.1016%2FJ.VIROL.2006.07.026

7 January 2021

based on heuristic

inferred from DOI database lookup

Identifiers

Sitelinks

Wikipedia(0 entries)

Wikibooks(0 entries)

Wikinews(0 entries)

Wikiquote(0 entries)

Wikisource(0 entries)

Wikiversity(0 entries)

Wikivoyage(0 entries)

Wiktionary(0 entries)

Multilingual sites(0 entries)

Retrieved from "https://www.wikidata.org/w/index.php?title=Q38926279&oldid=1504522254"